Table 2 Baseline characteristics of patients, stratified by presence of mechanical valves
All patients | Mechanical valve | No mechanical valve | ||||
|---|---|---|---|---|---|---|
N = 411 | N = 257 | N = 154 | ||||
Indication for warfarin therapy - no. (%) | ||||||
Mechanical heart valve replacement (any) | 257 | 62.5% | 257 | 100.0% | ||
Mechanical mitral valve replacement | 212 | 51.3% | 212 | 82.5% | ||
Mechanical aortic valve replacement | 121 | 29.0% | 121 | 47.1% | ||
Mitral stenosis (native valve) | 13 | 3.2% | 13 | 8.4% | ||
Atrial fibrillation or atrial flutter | 318 | 77.4% | 186 | 72.4% | 132 | 85.7% |
CHAD2S2-VASc (for non-valvular AF; N = 119) - mean ± S.D. | 3.34 | ± 1.93 | ||||
CHAD2S2-VASc ≥2 (for non-valvular AF; N = 119) | 96 | 80.7% | ||||
Deep vein thrombosis or pulmonary embolism | 4 | 1.0% | 0 | 0.0% | 4 | 2.6% |
Intracardiac thrombus | 14 | 3.4% | 0 | 0.0% | 14 | 9.1% |
Medications - no. (%) | ||||||
Any anti-platelet therapy | 69 | 16.8% | 20 | 7.8% | 49 | 31.8% |
Aspirin | 68 | 16.6% | 20 | 7.8% | 48 | 31.2% |
P2Y12 inhibitor | 5 | 1.2% | 1 | 0.4% | 4 | 2.6% |
Statin | 153 | 37.2% | 78 | 30.4% | 75 | 48.7% |
ACE inhibitor or ARB | 215 | 52.3% | 117 | 45.5% | 98 | 63.6% |
Beta-blocker | 220 | 53.5% | 118 | 45.9% | 102 | 66.2% |
Diuretics | 312 | 75.9% | 196 | 76.3% | 116 | 75.3% |
Pre-operative low molecular weight heparin | 235 | 57.2% | 181 | 70.4% | 54 | 35.0% |